Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease

被引:170
作者
Bilodeau, Steve
Vallette-Kasic, Sophie
Gauthier, Yves
Figarella-Branger, Dominique
Brue, Thierry
Berthelet, France
Lacroix, Andre
Batista, Dalia
Stratakis, Constantine
Hanson, Jeanette
Meij, Bjorn
Drouin, Jacques
机构
[1] Clin Res Inst Montreal, Genet Mol Lab, Montreal, PQ H2W 1R7, Canada
[2] Univ Mediterranee, Lab Interact Cellulaires Neuroendocriniennes, Inst Jean Roche, CNRS,UMR 6544, F-13385 Marseille, France
[3] CHUM, Hotel Dieu, Dept Med, Res Ctr, Montreal, PQ H2W 1T8, Canada
[4] NICHHD, Dev Endocrinol Branch, SEGEN, Bethesda, MD 20892 USA
[5] Univ Utrecht, Fac Vet Med, Dept Clin Sci & Compan Anim, NL-3508 TD Utrecht, Netherlands
关键词
repression; nuclear receptor; Swi/Snf; pituitary tumors; POMC; Cushing;
D O I
10.1101/gad.1444606
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Negative feedback regulation of the proopiomelanocortin ( POMC) gene by the glucocorticoid (Gc) receptor (GR) is a critical feature of the hypothalamo-pituitary-adrenal axis, and it is in part exerted by trans-repression between GR and the orphan nuclear receptors related to NGFI-B. We now show that Brg1, the ATPase subunit of the Swi/Snf complex, is essential for this trans-repression and that Brg1 is required in vivo to stabilize interactions between GR and NGFI-B as well as between GR and HDAC2. Whereas Brg1 is constitutively present at the POMC promoter, recruitment of GR and HDAC2 is ligand-dependent and results in histone H4 deacetylation of the POMC locus. In addition, GR-dependent repression inhibits promoter clearance by RNA polymerase II. Thus, corecruitment of repressor and activator at the promoter and chromatin modification jointly contribute to trans-repression initiated by direct interactions between GR and NGFI-B. Loss of Brg1 or HDAC2 should therefore produce Gc resistance, and we show that similar to 50% of Gc-resistant human and dog corticotroph adenomas, which are the hallmark of Cushing disease, are deficient in nuclear expression of either protein. In addition to providing a molecular basis for Gc resistance, these deficiencies may also contribute to the tumorigenic process.
引用
收藏
页码:2871 / 2886
页数:16
相关论文
共 51 条
  • [1] Diagnosis and complications of Cushing's syndrome: A consensus statement
    Arnaldi, G
    Angeli, A
    Atkinson, AB
    Bertagna, X
    Cavagnini, F
    Chrousos, GP
    Fava, GA
    Findling, JW
    Gaillard, RC
    Grossman, AB
    Kola, B
    Lacroix, A
    Mancini, T
    Mantero, F
    Newell-Price, J
    Nieman, LK
    Sonino, N
    Vance, ML
    Giustina, A
    Boscaro, M
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (12) : 5593 - 5602
  • [2] Rb enhances p160/SRC coactivator-dependent activity of nuclear receptors and hormone responsiveness
    Batsché, E
    Desroches, J
    Bilodeau, S
    Gauthier, Y
    Drouin, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (20) : 19746 - 19756
  • [3] Retinoblastoma and the related pocket protein p107 act as coactivators of NeuroD1 to enhance gene transcription
    Batsché, E
    Moschopoulos, P
    Desroches, J
    Bilodeau, S
    Drouin, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (16) : 16088 - 16095
  • [4] Opposing effects of Ctk1 kinase and Fcp1 phosphatase at Ser 2 of the RNA polymerase II C-terminal domain
    Cho, EJ
    Kobor, MS
    Kim, M
    Greenblatt, J
    Buratowski, S
    [J]. GENES & DEVELOPMENT, 2001, 15 (24) : 3319 - 3329
  • [5] Localized recruitment of a chromatin-remodeling activity by an activator in vivo drives transcriptional elongation
    Corey, LL
    Weirich, CS
    Benjamin, IJ
    Kingston, RE
    [J]. GENES & DEVELOPMENT, 2003, 17 (11) : 1392 - 1401
  • [6] Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137
  • [7] The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1:: Molecular mechanisms for gene repression
    De Bosscher, K
    Vanden Berghe, W
    Haegeman, G
    [J]. ENDOCRINE REVIEWS, 2003, 24 (04) : 488 - 522
  • [8] Clinical development of histone deacetylase inhibitors as anticancer agents
    Drummond, DC
    Noble, CO
    Kirpotin, DB
    Guo, ZX
    Scott, GK
    Benz, CC
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2005, 45 : 495 - 528
  • [9] Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex
    Fryer, CJ
    Archer, TK
    [J]. NATURE, 1998, 393 (6680) : 88 - 91
  • [10] TISSUE-SPECIFIC REGULATION OF PITUITARY PROOPIOMELANOCORTIN GENE-TRANSCRIPTION BY CORTICOTROPIN-RELEASING HORMONE, 3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE, AND GLUCOCORTICOIDS
    GAGNER, JP
    DROUIN, J
    [J]. MOLECULAR ENDOCRINOLOGY, 1987, 1 (10) : 677 - 682